Literature DB >> 12120757

Production of nitric oxide, but not prostacyclin, is reduced in klotho mice.

Tetsuya Nakamura1, Yuichiro Saito, Yoshio Ohyama, Hiroaki Masuda, Hiroyuki Sumino, Makoto Kuro-o, Youichi Nabeshima, Ryozo Nagai, Masahiko Kurabayashi.   

Abstract

A novel murine model of aging (kl/kl mice) has been developed by in vivo mutagenesis. We analyzed endothelial function in this strain. Ring preparations of the thoracic aorta were obtained from 6- to 9-week old wild-type (+/+) and heterozygous (kl/+) klotho mice. The aortas of kl/+ mice showed an exaggerated contractile response to norepinephrine and attenuated vasodilator responses to acetylcholine and lecithinized superoxide dismutase (SOD) compared to +/+ mice. The response to sodium nitroprusside was unaltered in kl/+ mice. The contraction in response to norepinephrine was augmented by treatment with N(G)-nitro-L-arginine methyl ester (L-NAME, 10(-5) M) to a greater extent in +/+ mice than in kl/+ mice. Treatment with L-NAME abolished the vasodilator responses to both acetylcholine and lecithinized SOD. NO metabolites (NO2- and NO3-) and cGMP concentrations in the urine were significantly reduced in kl/+ mice compared to +/+ mice. However, the urinary excretion of 6-keto-prostaglandin F1alpha was unaltered. There was little immunostaining for NO synthase and vascular endothelial growth factor (VEGF) in the aorta of kl/+ mice. No immunostaining for NO synthase was noted in the aorta of kl/kl mice. The expression of the klotho gene product may have a role in the regulation of VEGF expression and is tightly linked to endothelial release of NO.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12120757     DOI: 10.1254/jjp.89.149

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  17 in total

Review 1.  Mechanisms of vascular aging: new perspectives.

Authors:  Zoltan Ungvari; Gabor Kaley; Rafael de Cabo; William E Sonntag; Anna Csiszar
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-06-24       Impact factor: 6.053

2.  Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD.

Authors:  Giovanni Tripepi; Barbara Kollerits; Daniela Leonardis; Mahamut Ilker Yilmaz; Maurizio Postorino; Danilo Fliser; Francesca Mallamaci; Florian Kronenberg; Carmine Zoccali
Journal:  J Am Soc Nephrol       Date:  2014-08-22       Impact factor: 10.121

3.  Plasma klotho and cardiovascular disease in adults.

Authors:  Richard D Semba; Anne R Cappola; Kai Sun; Stefania Bandinelli; Mansi Dalal; Candace Crasto; Jack M Guralnik; Luigi Ferrucci
Journal:  J Am Geriatr Soc       Date:  2011-08-24       Impact factor: 5.562

Review 4.  Secreted klotho and chronic kidney disease.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

5.  Baseline FGF23 is Associated with Cardiovascular Outcome in Incident PD Patients.

Authors:  Hyo Jin Kim; Miseon Park; Hayne Cho Park; Jong Cheol Jeong; Dong Ki Kim; Kwon Wook Joo; Young-Hwan Hwang; Jaeseok Yang; Curie Ahn; Kook-Hwan Oh
Journal:  Perit Dial Int       Date:  2014-09-02       Impact factor: 1.756

Review 6.  Klotho and kidney disease.

Authors:  Ming-Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  J Nephrol       Date:  2010 Nov-Dec       Impact factor: 3.902

7.  Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells.

Authors:  Beatrice Richter; Jacqueline Haller; Dieter Haffner; Maren Leifheit-Nestler
Journal:  Pflugers Arch       Date:  2016-07-22       Impact factor: 3.657

Review 8.  FGF23 associated bone diseases.

Authors:  Eryuan Liao
Journal:  Front Med       Date:  2013-03-09       Impact factor: 4.592

9.  Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.

Authors:  Johan Ärnlöv; Axel C Carlsson; Johan Sundström; Erik Ingelsson; Anders Larsson; Lars Lind; Tobias E Larsson
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-18       Impact factor: 8.237

Review 10.  αKlotho and Chronic Kidney Disease.

Authors:  J A Neyra; M C Hu
Journal:  Vitam Horm       Date:  2016-03-24       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.